Literature DB >> 15781659

Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells.

Eddy Pasquier1, Stéphane Honore, Bertrand Pourroy, Mary Ann Jordan, Maxime Lehmann, Claudette Briand, Diane Braguer.   

Abstract

Microtubule-targeted drugs such as paclitaxel exhibit potent antiangiogenic activity at very low concentrations, but the mechanism underlying such an effect remains unknown. To understand the involvement of microtubules in angiogenesis, we analyzed the dynamic instability behavior of microtubules in living endothelial cells [human microvascular endothelial cells (HMEC-1) and human umbilical vascular endothelial cells (HUVEC)] following 4 hours of paclitaxel treatment. Unexpectedly, antiangiogenic concentrations of paclitaxel (0.1-5 nmol/L) strongly increased microtubule overall dynamicity in both HMEC-1 (86-193%) and HUVEC (54-83%). This increase was associated with increased microtubule growth and shortening rates and extents and decreased mean duration of pauses. The enhancement of microtubule dynamics by paclitaxel seemed to be specific to antiangiogenic concentrations and to endothelial cells. Indeed, cytotoxic concentration (100 nmol/L) of paclitaxel suppressed microtubule dynamics by 40% and 54% in HMEC-1 and HUVECs, respectively, as observed for all tested concentrations in A549 tumor cells. After 4 hours of drug incubation, antiangiogenic concentrations of paclitaxel that inhibited endothelial cell proliferation without apoptosis (1-5 nmol/L) induced a slight decrease in anaphase/metaphase ratio, which was more pronounced and associated with increased mitotic index after 24 hours of incubation. Interestingly, the in vitro antiangiogenic effect also occurred at 0.1 nmol/L paclitaxel, a concentration that did not alter mitotic progression and endothelial cell proliferation but was sufficient to increase interphase microtubule dynamics. Altogether, our results show that paclitaxel mediates antiangiogenesis by an increase in microtubule dynamics in living endothelial cells and suggest that the impairment of interphase microtubule functions is responsible for the inhibition of angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15781659     DOI: 10.1158/0008-5472.CAN-04-2624

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  42 in total

1.  Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer.

Authors:  Robert L Coleman; Linda R Duska; Pedro T Ramirez; John V Heymach; Aparna A Kamat; Susan C Modesitt; Kathleen M Schmeler; Revathy B Iyer; Michael E Garcia; Debbie L Miller; Edward F Jackson; Chaan S Ng; Vikas Kundra; Robert Jaffe; Anil K Sood
Journal:  Lancet Oncol       Date:  2011-10-10       Impact factor: 41.316

Review 2.  Weekly paclitaxel in the treatment of recurrent ovarian cancer.

Authors:  Richard D Baird; David S P Tan; Stan B Kaye
Journal:  Nat Rev Clin Oncol       Date:  2010-08-03       Impact factor: 66.675

3.  Inhibition of cell migration and cell division correlates with distinct effects of microtubule inhibiting drugs.

Authors:  Hailing Yang; Anutosh Ganguly; Fernando Cabral
Journal:  J Biol Chem       Date:  2010-08-09       Impact factor: 5.157

4.  A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study.

Authors:  Robert L Coleman; William E Brady; D Scott McMeekin; Peter G Rose; John T Soper; Samuel S Lentz; James S Hoffman; Mark S Shahin
Journal:  Gynecol Oncol       Date:  2011-04-15       Impact factor: 5.482

Review 5.  Angiosarcomas and taxanes.

Authors:  Nicolas Penel; Amélie Lansiaux; Antoine Adenis
Journal:  Curr Treat Options Oncol       Date:  2007-12-08

Review 6.  Antivascular actions of microtubule-binding drugs.

Authors:  Edward L Schwartz
Journal:  Clin Cancer Res       Date:  2009-04-07       Impact factor: 12.531

7.  Anti-angiogenic effects of the tubulysin precursor pretubulysin and of simplified pretubulysin derivatives.

Authors:  S Rath; J Liebl; R Fürst; A Ullrich; J L Burkhart; U Kazmaier; J Herrmann; Rolf Müller; M Günther; L Schreiner; E Wagner; A M Vollmar; S Zahler
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

8.  Multicompartimental nanoparticles for co-encapsulation and multimodal drug delivery to tumor cells and neovasculature.

Authors:  Lívia Palmerston Mendes; Marilisa Pedroso Nogueira Gaeti; Paulo Henrique Marcelino de Ávila; Marcelo de Sousa Vieira; Bruna Dos Santos Rodrigues; Renato Ivan de Ávila Marcelino; Lílian Cristina Rosa Dos Santos; Marize Campos Valadares; Eliana Martins Lima
Journal:  Pharm Res       Date:  2013-10-30       Impact factor: 4.200

9.  MVL-PLA2, a snake venom phospholipase A2, inhibits angiogenesis through an increase in microtubule dynamics and disorganization of focal adhesions.

Authors:  Amine Bazaa; Eddy Pasquier; Céline Defilles; Ines Limam; Raoudha Kessentini-Zouari; Olfa Kallech-Ziri; Assou El Battari; Diane Braguer; Mohamed El Ayeb; Naziha Marrakchi; José Luis
Journal:  PLoS One       Date:  2010-04-12       Impact factor: 3.240

10.  Enhanced specific delivery and targeting of oncolytic Sindbis viral vectors by modulating vascular leakiness in tumor.

Authors:  J-C Tseng; T Granot; V DiGiacomo; B Levin; D Meruelo
Journal:  Cancer Gene Ther       Date:  2009-10-02       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.